Taliglucerase alfa belongs to the class of medications called enzyme replacement therapies. Specifically, it is a replacement for the enzyme glucocerebrosidase, a protein that is normally found in the body and is responsible for breaking down certain types of fatty substances.
Available form
Powder
Dosage
Manufacturer
Pfizer
We won't bore you with the details, but Health Canada requires you to sign in.
By proceeding you agree to our Terms of Use & Privacy Policy
The appropriate dose of taliglucerase alfa is based on body weight and varies from person to person, depending on how well it is tolerated and how much is needed to be effective.
Taliglucerase alfa is given by intravenous (into a vein) infusion over 1 to 2 hours, every 2 weeks.
Careful handling of Elelyso (Taliglucerase-alfa) is required, and it is commonly given in a hospital or similar setting with access to sterile equipment for preparation. Under some circumstances, you may be taught to prepare and administer Elelyso (Taliglucerase-alfa) at home.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
It is important Elelyso (Taliglucerase-alfa) be given exactly as recommended by your doctor. If you miss an appointment to receive taliglucerase alfa, contact your doctor as soon as possible to reschedule your appointment.
If you are storing Elelyso (Taliglucerase-alfa) at home, keep it in a refrigerator (2°-8°C) and transport refrigerated (2°-8°C). Protect from light. Keep the vial in the outer carton.
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes Elelyso (Taliglucerase-alfa). If you are concerned about side effects, discuss the risks and benefits of Elelyso (Taliglucerase-alfa) with your doctor.
The following side effects have been reported by at least 1% of people taking Elelyso (Taliglucerase-alfa). Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
Although most of the side effects listed below don't happen very often, they could lead to serious problems if you do not seek medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Stop taking the medication and seek immediate medical attention if any of the following occur:
Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking Elelyso (Taliglucerase-alfa).
Each vial of sterile, non-pyrogenic, white-to-off-white lyophilyzed powder for reconstitution and intravenous infusion contains 212 units of taliglucerase alfa to allow 200 units to be withdrawn from the vial. Nonmedicinal ingredients: mannitol, sodium citrate, polysorbate 80, and citric acid anhydrous to adjust pH.
Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications that you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them. Depending on your specific circumstances, your doctor may want you to:
An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.
Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Elelyso (Taliglucerase-alfa).
Allergic reactions: Some people may develop a serious allergic reaction to Elelyso (Taliglucerase-alfa). This reaction can occur up to 24 hours after receiving a dose of taliglucerase alfa. Signs of an allergic reaction include a severe rash, hives, swollen face or throat, or difficulty breathing. If these occur, get immediate medical attention.
Dizziness: Taliglucerase may cause dizziness. Do not drive, operate machinery, or perform other hazardous tasks until you have determined how Elelyso (Taliglucerase-alfa) affects you.
Infusion-related reactions: As with other enzyme therapies, taliglucerase alfa can cause severe infusion-related reactions, including severe allergic reactions. Your health care provider will closely monitor you during and after the infusion, and may give you other medications before you receive the taliglucerase alfa, to prevent these reactions.
If you experience symptoms of an infusion reaction, such as fever, chills, difficulty breathing, tightness of chest or throat, stomach upset, and rash, tell your health care provider immediately. Symptoms can usually be reduced by slowing down or temporarily stopping the medication, as well as using other medications to treat the reaction.
It is important to take the medication(s) recommended by your doctor before your infusion of taliglucerase alfa. If you experience a severe infusion reaction, your doctor will give you additional medications to treat the reaction. Ask your doctor for more information.
Pregnancy: Elelyso (Taliglucerase-alfa) should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking Elelyso (Taliglucerase-alfa), contact your doctor immediately.
Breast-feeding: It is not known if taliglucerase alfa passes into breast milk. If you are a breast-feeding mother and are taking Elelyso (Taliglucerase-alfa), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
Children: The safety and effectiveness of using Elelyso (Taliglucerase-alfa) have not been established for children less than 2 years old.
price lookup
Total no. of dose(s)
Manufacturer
Insurance coverage
Dosage
*Actual pricing may differ. Medication is only available by prescription. The cost may be subsidised by your provincial or private health plan.
price details
Total (CAD)
--*
Drug info not available
It’s like having us in your pocket, putting you first in every interaction.
Your medication is delivered to you at no added cost.
Call, text, email—whatever works for you. We’re humans, ready to help.
Discreet with real-time updates. Go about your day, your meds are on the way.
2025 Pocketpills
Pocketpills is not a pharmacy
or a drug manufacturer
